

ChemoCentryx, Inc.
Form SC 13D/A
August 25, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

CHEMOCENTRYX, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16383L106

(CUSIP Number)

Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
England
Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 9, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Cusip No. 16383L106 13 D/A2 Page 2 of 7

1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
GlaxoSmithKline plc
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
2. (a)
(b)
3. SEC USE ONLY
4. SOURCE OF FUNDS (see instructions)
WC
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
CITIZENSHIP OR PLACE OF ORGANIZATION
6. England and Wales

- | | |
|---|------------------------------|
| | 7. SOLE VOTING POWER |
| | 7,343,492 |
| | 8. SHARED VOTING POWER |
| | -0- |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 9. SOLE DISPOSITIVE POWER |
| | 7,343,492 |
| | 10. SHARED DISPOSITIVE POWER |
| | -0- |

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,343,492 (1)
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
15.4% (2)
- 14.

TYPE OF REPORTING PERSON (see instructions)

CO

Footnotes:

(1) Shares of Common Stock are held of record by Glaxo Group Limited, an indirect wholly owned subsidiary of GlaxoSmithKline plc.

(2) Based on 47,762,362 shares of Common Stock outstanding as of July 29, 2016.

Cusip No. 16383L106 13 D/A2 Page 3 of 7

Item 1. Security and Issuer.

This Amendment No. 2 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on February 23, 2012 (as amended by Amendment No. 1 filed on May 1, 2013, the "Schedule 13D" and as amended by this Amendment No. 2, the "Statement") with respect to the shares of common stock, par value \$0.001 per share (the "Common Stock"), of ChemoCentryx, Inc., a Delaware corporation (the "Issuer"). GlaxoSmithKline plc is filing this amendment to reflect its new percentage beneficial ownership in the Issuer, which has decreased as a result of an increase in the outstanding shares of Common Stock of the Issuer. The Issuer's principle executive offices are located at 850 Maude Avenue, Mountain View, California 94043. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

Item 2. Identity and Background.

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 as attached to Amendment No. 1 in its entirety, and replacing it with Schedule 1 attached hereto.

Item 5. Interest in Securities of the Issuer.

The response set forth in the first paragraph of Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

(a) GlaxoSmithKline plc beneficially owns 7,343,492 shares of Common Stock, which represents 15.4% of 47,762,362 shares of Common Stock outstanding as of July 29, 2016.

Cusip No. 16383L106 13 D/A2 Page 4 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 25, 2016

GLAXOSMITHKLINE PLC

By: /s/ Victoria A. Whyte
Victoria A. Whyte
Authorized Signatory

Cusip No. 16383L106 13 D/A2 Page 5 of 7

SCHEDULE 1

Name	Business Address	Principal Occupation or Employment	Citizenship
<u>Board of Directors</u>			
	980 Great West Road		
Sir Andrew Witty	Brentford Middlesex, England	Executive Director and Chief Executive Officer	British
	TW8 9GS 980 Great West Road		
Professor Sir Roy Anderson	Brentford Middlesex, England	Company Director	British
	TW8 9GS 980 Great West Road		
Manvinder Singh Banga	Brentford Middlesex, England	Company Director	Indian
	TW8 9GS 980 Great West Road		
Stacey Cartwright	Brentford Middlesex, England	Company Director	British
	TW8 9GS 980 Great West Road		
Simon Dingemans	Brentford Middlesex, England	Executive Director and Chief Financial Officer	British
	TW8 9GS 980 Great West Road		
Lynn Elsenhans	980 Great West Road	Company Director	US

Edgar Filing: ChemoCentryx, Inc. - Form SC 13D/A

Brentford

Middlesex, England

TW8 9GS
980 Great West
Road

Dr. Jesse Goodman	Brentford Middlesex, England	Company Director	US
	TW8 9GS 980 Great West Road		
Sir Philip Hampton	Brentford Middlesex, England	Chairman and Company Director	British
	TW8 9GS 980 Great West Road		
Judy Lewent	Brentford Middlesex, England	Company Director	US
	TW8 9GS 980 Great West Road		
Urs Rohner	Brentford Middlesex, England	Company Director	Swiss
	TW8 9GS 709 Swedeland Road,		
Dr. Moncef Slaoui	King of Prussia PA, 19406	Executive Director and Chairman, Global Vaccines	Moroccan, Belgian & US

Cusip No. 16383L106 13 D/A2 Page 6 of 7

	980 Great West Road		
Dr. Vivienne Cox	Brentford Middlesex, England TW8 9GS	Company Director	British
<u>Corporate Executive Team</u>			
	980 Great West Road		
Sir Andrew Witty	Brentford Middlesex, England TW8 9GS 980 Great West Road	Executive Director and Chief Executive Officer	British
Roger Connor	Brentford Middlesex, England TW8 9GS 980 Great West Road	President, Global Manufacturing & Supply	Irish
Simon Dingemans	Brentford Middlesex, England TW8 9GS 980 Great West Road	Executive Director and Chief Financial Officer	British
Nick Hirons	Brentford Middlesex TW8 9GS	Senior Vice President, Global Ethics and Compliance	British & US
Abbas Hussain	TW8 9GS	President, Global Pharmaceuticals	British

Edgar Filing: ChemoCentryx, Inc. - Form SC 13D/A

980 Great West
Road

Brentford

Middlesex, England

TW8 9GS
980 Great West
Road

David Redfern	Brentford Middlesex, England TW8 9GS 709 Swedeland Road,	Chief Strategy Officer	British
Dr. Moncef Slaoui	King of Prussia PA, 19406	Executive Director Chairman, Global Vaccines	Moroccan, Belgian & US
Claire Thomas	980 Great West Road Brentford Middlesex, England	Senior Vice President, Human Resources	British
Philip Thomson	980 Great West Road Brentford Middlesex, England	Senior Vice President, Global Communications and Government Affairs	British
Daniel Troy	TW8 9GS The Navy Yard 5 Crescent Drive Philadelphia, PA 19112	Senior Vice President & General Counsel	US

Cusip No. 16383L106 13 D/A2 Page 7 of 7

980 Great West Road

Dr. Patrick Vallance Brentford President, Pharmaceuticals R&D British
Middlesex, England

TW8 9GS
980 Great West Road

Emma Walmsley Brentford Chief Executive Officer, GSK Consumer Healthcare British
Middlesex, England

TW8 9GS